News
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...
Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...
On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...
President Donald Trump said his administration is prepared to increase the tariffs it plans to impose on pharmaceuticals up ...
Pharmaceuticals account for the bulk of Irish exports to the US and any change, or even uncertainty, on tariffs poses major ...
Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...
Pharmaceutical Technology on MSN4d
Pfizer shares rise 3% after upping profit forecast for 2025
While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback